- Home
- MGNX vs ENGN Comparison
MGNX vs ENGN Comparison
Compare MGNX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- ENGN
- Stock Information
- Founded
- MGNX 2000
- ENGN 1999
- Country
- MGNX United States
- ENGN Canada
- Employees
- MGNX N/A
- ENGN N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- MGNX Health Care
- ENGN
- Exchange
- MGNX Nasdaq
- ENGN Nasdaq
- Market Cap
- MGNX 257.3M
- ENGN 293.1M
- IPO Year
- MGNX 2013
- ENGN N/A
- Fundamental
- Price
- MGNX $3.24
- ENGN $7.68
- Analyst Decision
- MGNX Buy
- ENGN Strong Buy
- Analyst Count
- MGNX 11
- ENGN 7
- Target Price
- MGNX $8.57
- ENGN $31.43
- AVG Volume (30 Days)
- MGNX 770.4K
- ENGN 70.1K
- Earning Date
- MGNX 11-05-2024
- ENGN 09-10-2024
- Dividend Yield
- MGNX N/A
- ENGN N/A
- EPS Growth
- MGNX N/A
- ENGN N/A
- EPS
- MGNX N/A
- ENGN N/A
- Revenue
- MGNX $141,329,000.00
- ENGN N/A
- Revenue This Year
- MGNX $119.63
- ENGN N/A
- Revenue Next Year
- MGNX N/A
- ENGN N/A
- P/E Ratio
- MGNX N/A
- ENGN N/A
- Revenue Growth
- MGNX 16.68
- ENGN N/A
- 52 Week Low
- MGNX $2.95
- ENGN $4.42
- 52 Week High
- MGNX $21.88
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- ENGN 44.37
- Support Level
- MGNX $3.61
- ENGN $7.30
- Resistance Level
- MGNX $5.10
- ENGN $7.97
- Average True Range (ATR)
- MGNX 0.35
- ENGN 0.54
- MACD
- MGNX -0.10
- ENGN -0.14
- Stochastic Oscillator
- MGNX 4.62
- ENGN 21.60
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.